Kenn Samala· @KSamalaMD · X·· 4 days agoScore70
Body
ctDNA analysis of the CROWN trial by @bensolomon1 #ESMO26
✅️ early progressors : higher no. Of mutations, including TP53
✅️ inflammatory response was the predominant EP-associated pathway
25 views · 0 likes · 0 reposts · 2 replies
Conference abstracts
2636ROmatched by Rapid oral 1: NSCLC, metastatic
Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgReplies in this thread
- Kenn Samala@KSamalaMD
@bensolomon1 ✅️ ctDNA noted new ALK resistance mutations ✅️ higher mutations and higher inflammatory response -> may help identify early progressors (question is, what can we do for them, tx escalation?) #ESMO26
- Kenn Samala@KSamalaMD
@bensolomon1 Lorlatinib effective regardless of ALK variant #ESMO26
Source: Kenn Samala · x.com